ClinicalTrials.gg

Program

poseltinib

Also written as “LY3337641”, “NB02 (Poseltinib)” and “LY3337641 (T1)”.

Its studies are mostly in Arthritis, Rheumatoid · Lymphoma, Non-Hodgkin, led by 3 companies.

Furthest: phase 2, since Dec 9, 20156 company-led studies, 1 open or runningNext primary completion: Dec 31, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly40 open or runningphase 2since Dec 9, 2015Dec 9, 2015none ahead
Hanmi Pharmaceutical10 open or runningphase 1since Jan 7, 2013Jan 7, 2013none ahead
NOBO Medicine11 open or runningphase 1since Jul 3, 2025Jul 3, 2025Dec 31, 2026phase 1 · NCT07114367

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 7, 2013First study: phase 1 study in Arthritis, RheumatoidNew to Hanmi PharmaceuticalHanmi Pharmaceutical · NCT01765478 · 62 enrolled · Netherlands
  2. Dec 9, 2015Eli Lilly's first study: phase 2 study in Arthritis, RheumatoidNew to Eli LillyEli Lilly · NCT02628028 · 286 enrolled · United States, Argentina, Australia and more
  3. Sep 21, 2016Phase 1 study in HealthyEli Lilly · NCT02914379 · 6 enrolled · United States
  4. Mar 14, 20172 phase 1 studies in HealthyEli Lilly · NCT03083561, NCT03099148
  5. Jul 3, 2025NOBO Medicine's first study: phase 1 study in Lymphoma, Non-HodgkinNew to NOBO MedicineNOBO Medicine · NCT07114367 · 9 planned · South Korea

Ahead

  1. Dec 31, 2026Primary completion: phase 1 study in Lymphoma, Non-HodgkinNOBO Medicine · NCT07114367

TargetBeta

BTK →read by rule
“An inhibitor of Bruton's tyrosine kinase (BTK) ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor; Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule

Other programs on BTK

ProgramCompanyFurthest phaseStudies
ibrutinibruleJohnson & Johnsonphase 478
acalabrutinibruleAstraZenecaphase 455
zanubrutinibruleBeOne Medicinesphase 435
pirtobrutinibruleEli Lillyphase 430
ritlecitinibrulePfizerphase 342
orelabrutinibruleInnoCare Pharmaphase 327
rilzabrutinibruleSanofiphase 323
evobrutinibruleMerck KGaA, Darmstadt, Germanyphase 320
fenebrutinibHoffmann-La Rochephase 318
nemtabrutinibMerckphase 316
rocbrutinibruleLupeng Pharmaceuticalphase 315
tirabrutinibruleGilead Sciencesphase 313

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07114367Lymphoma, Non-Hodgkin · South Korea1RecruitingNOBO MedicineDec 31, 20269
NCT03099148Healthy · Singapore1CompletedEli LillyMay 31, 201729
NCT03083561Healthy · United States1CompletedEli LillyMay 25, 201736
NCT02914379Healthy · United States1CompletedEli LillyNov 20166
NCT02628028Arthritis, Rheumatoid · United States, Argentina, Australia and more2TerminatedEli LillyApr 25, 2018286
NCT01765478Arthritis, Rheumatoid · Netherlands1CompletedHanmi PharmaceuticalNov 201462

How it is read

Names in the registry

  • “LY3337641”, 2 entries
  • “NB02 (Poseltinib)”, 1 entry
  • “LY3337641 (T1)”, 1 entry
  • “LY3337641 (T2)”, 1 entry
  • “[¹⁴C]-LY3337641”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.